uniQure's Novel HD Gene Therapy Tests FDA Flexibility with Phase I/II Data Amidst Heightened Scrutiny

UniQure Ready for Potential FDA Adcomm on Huntington's Gene Therapy

UniQure is prepared for a potential FDA advisory committee meeting for its investigational Huntington’s disease gene therapy, AMT-130, despite recent regulatory uncertainties affecting other rare disease assets. The company anticipates priority review due to its Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations. CMO Walid Abi-Saab expressed the company's readiness to engage with the independent probe, emphasizing that each program is evaluated on its own merits. This comes as the rare disease sector experiences "jitters" from increased FDA scrutiny, exemplified by recent adcomm outcomes for Capricor's deramiocel and Replimune's RP1.

• UniQure's CMO, Walid Abi-Saab, confirmed the company's readiness and welcome for a potential FDA advisory committee meeting for AMT-130. The company expects priority review given its Breakthrough Therapy and Regenerative Medicine Advanced Therapy designations, indicating confidence in its data and a proactive approach to regulatory scrutiny.
• The press release highlights a significant degree of "jitters" across the rare disease space due to persistent regulatory uncertainty. This is underscored by recent high-stakes advisory committee scrutinies for Capricor Therapeutics' deramiocel for Duchenne muscular dystrophy cardiomyopathy and Replimune's RP1 for advanced melanoma, both of which faced prior FDA setbacks and controversial decisions.
• UniQure previously experienced inconsistent feedback from the FDA regarding AMT-130, including a reversal on the sufficiency of Phase 1/2 data for a BLA and the necessity of a sham surgery control. These reversals, which occurred after the departure of former FDA officials Vinay Prasad and Marty Makary, ultimately led to the FDA agreeing that three-year Phase 1/2 data could support an application without a sham surgery.

The Persistent Need for Novel Huntington’s Disease Therapies

Despite decades of research, Huntington's disease (HD) remains a devastating neurodegenerative disorder without a cure or disease-modifying therapy. Current management relies almost exclusively on symptomatic approaches, while promising experimental strategies face substantial translational and logistical hurdles before reaching patients.

• No disease-modifying options exist: There is currently no cure for HD, nor any therapy capable of altering the progressive course of the disease; available treatments are limited to symptomatic management aimed at reducing symptom severity rather than addressing underlying pathology.

• Rehabilitation guidance is underdeveloped: Few studies have examined rehabilitative interventions in HD, and no formal clinical guidelines currently exist to inform standardized rehabilitation practice.

• Experimental strategies require invasive delivery: Approaches such as deep brain stimulation, neurotrophic factor delivery, cell transplantation, HTT gene silencing (via RNA interference or antisense oligonucleotides), and intrabody delivery all necessitate neurosurgical intervention—either for electrode implantation or for direct brain delivery of molecules, viruses, or cells that cannot cross the blood-brain barrier via oral or intravenous administration.

• Efficacy and safety of novel modalities remain unproven: The clinical efficacy of these experimental strategies has yet to be established in HD patients. Similarly, gene therapy platforms—including antisense oligonucleotides, small interfering RNAs, zinc finger proteins, and CRISPR-Cas9-based techniques—still require verification of both efficacy and long-term safety profiles.

• Cell therapy faces translational barriers: Approaches using embryonic stem cells, induced pluripotent stem cells, mesenchymal stromal cells, and neural stem cells continue to encounter significant challenges in moving from preclinical models into clinical practice.

• Research and dissemination gaps persist: The field shows underrepresentation of mental health impacts in HD research, geographic disparities in research output, and narrow dissemination across journals. Global collaboration remains limited, with research activity concentrated among a small number of countries and author groups—constraining the pace and breadth of therapeutic innovation.

Understanding the Genetic Basis of Huntington’s Disease

Huntington's disease (HD) originates from an expansion of the CAG trinucleotide repeat in exon 1 of the huntingtin gene (HTT) on chromosome 4, with expansions beyond 36 repeats producing an abnormally elongated polyglutamine tract in the huntingtin protein. This structurally aberrant protein is proteolytically processed into N-terminal fragments—cleavage sites encoded by exon 12 are particularly important—that misfold and accumulate as insoluble aggregates within neuronal nuclei and cytoplasm, including ubiquitinated neuronal intranuclear inclusions. Notably, not all mutant huntingtin fragments are equally toxic, and these aggregates sequester various proteins, especially transcription factors, disrupting normal cellular functioning. The mutation compromises the huntingtin protein's structural integrity and its interactions across multiple cellular systems, driving cell dysfunction and stress responses that are particularly deleterious to vulnerable neuronal populations, notably the medium spiny neurons of the striatum, despite huntingtin being ubiquitously expressed across virtually all cell types and organ systems.

At the molecular level, HD pathogenesis converges on several interconnected pathways: autophagic and lysosomal impairment, mitochondrial dysfunction and free radical damage, disrupted intracellular transport, oxidative stress, neuroinflammation, and widespread transcriptional dysregulation. Genome-wide expression analysis of human prefrontal cortex reveals that nearly 19% of detected genes are differentially expressed in HD, predominantly up-regulated, with enrichment for immune response, neuroinflammatory, and developmental genes—including a homeotic gene set (Hox and related homeobox genes) almost exclusively expressed in HD. This transcriptional disturbance is linked to compromised activity of nuclear proteins such as CA150, a transcriptional coactivator that interacts with full-length huntingtin, is markedly overexpressed in HD brain tissue, forms aggregates partially colocalizing with ubiquitin, and whose repeat length modestly but significantly influences age of disease onset. Additional regulatory disruption occurs through microRNA dysregulation—miR-214 is upregulated in HD models, inversely correlating with HTT expression and repressing MFN2, thereby altering mitochondrial morphology and cell cycle distribution—and through GPCR-mediated mechanisms, wherein the striatal-enriched receptor Gpr52 stabilizes huntingtin via a cAMP-dependent, PKA-independent pathway involving Rab39B, with Gpr52 knockdown suppressing HD phenotypes in patient-derived neurons and Drosophila models. Calcium signaling is also profoundly disturbed: mutant huntingtin sensitizes NR2B-containing NMDA receptors and InsP3R1, producing supranormal calcium responses to glutamate, mitochondrial membrane potential collapse, and excitotoxic apoptosis of medium spiny neurons—effects preventable by NR2B and mGluR1/5 antagonists.

Cellular contributions to HD extend beyond neurons to glial populations, with astrocytes and microglia exhibiting pathology from early postnatal development, including increased reactive astrocytes (elevated GFAP with reduced proliferative capacity), fewer glial progenitors, more microglia, lower glutathione levels, heightened vulnerability to oxidative and proteasomal insults, and markedly reduced GDNF and mature-BDNF secretion. HD glia also show deregulated ubiquitin-proteasomal and autophagic systems, evidenced by elevated ubiquitination and p62 accumulation, reflecting defective protein quality control that parallels neuronal pathology. Dopamine-associated oxyradical stress further exacerbates mutant neuron vulnerability, triggering autophagic granule formation and lysosomal responses that colocalize with oxygen radicals and ubiquitin, potentially underlying the selective neuronal loss characteristic of HD. Collectively, whether neuroinflammation arises as a secondary response to neuronal degeneration or reflects cell-autonomous immune dysfunction remains unresolved, but the convergence of these genetic, transcriptional, proteostatic, mitochondrial, and glial mechanisms underscores the multifactorial and systemic nature of HD pathogenesis—highlighting therapeutic opportunities spanning huntingtin-lowering strategies, anti-inflammatory approaches, and modulation of proteostasis and synaptic transmission.

AMT-130: Clinical Data Supporting Its Regulatory Path

Published Phase I/II clinical data for AMT-130, uniQure's investigational one-time gene therapy for Huntington's disease (HD), demonstrate a favorable overall safety profile to date. AMT-130 employs an adeno-associated virus serotype 5 (AAV5) vector to deliver an engineered microRNA (miHTT) directly into the caudate and putamen via stereotactic intracerebral infusion, targeting the underlying pathology of HD—a progressive, autosomal dominant neurodegenerative disorder driven by expanded CAG repeats in the huntingtin (HTT) gene. Across reported follow-up periods, including 24-month interim results and more recent 36-month topline data, the safety findings have supported continued clinical development, though the publicly available literature does not detail specific adverse event types, frequencies, or treatment-related discontinuation rates.

Alongside this tolerability profile, early efficacy signals have been observed that reinforce the therapy's potential disease-modifying rationale. These include reductions in neurofilament light chain (NfL) levels—a biomarker of neuronal injury—and stabilization of motor and functional decline, with these effects appearing more pronounced in high-dose cohorts. The concurrent observation of safety and biomarker/functional stabilization has informed uniQure's engagement with the U.S. Food and Drug Administration regarding key elements of a potential accelerated approval pathway.

Despite these encouraging early results, the current evidence base remains limited to Phase I/II data, and long-term efficacy and broader clinical validation are still required to confirm durability of response and to fully characterize the safety profile across a larger, more diverse patient population.

The Evolving Treatment Landscape for Huntington’s Disease

Over the past five years, the Huntington’s disease (HD) treatment landscape has shifted from a near-total absence of disease-modifying options toward a more diversified pipeline, even as no therapy has yet demonstrated the ability to alter disease progression. Symptomatic management remains anchored by VMAT-2 inhibitors—tetrabenazine, deutetrabenazine, and valbenazine—which a meta-analysis of seven randomized trials (1,431 participants) confirmed provide statistically robust improvements in chorea, with reductions in UHDRS Total Motor Score (MD −3.80) and Total Maximal Chorea score (MD −3.05), and safety profiles comparable to placebo. By contrast, dopamine stabilizers such as pridopidine and ordopidine have not shown meaningful motor benefit, with Trial Sequential Analysis indicating that further data are needed before their clinical value can be established. Antisense oligonucleotide programs, once viewed as the most promising route to disease modification, suffered high-profile clinical failures, prompting a pivot toward alternative RNA-targeted and gene-based strategies, including splice modulation and siRNA approaches for HTT knockdown.

This pivot is exemplified by AMT-130, a one-time AAV5-delivered microRNA gene therapy administered via stereotactic infusion into the caudate and putamen, which has shown a favorable safety profile, reductions in neurofilament light chain, and stabilization of motor and functional decline in early Phase I/II data—particularly at higher doses—suggesting a genuine move from symptomatic care toward disease modification. Complementary innovation is emerging around somatic CAG expansion biology, with intraventricular divalent siRNA targeting the modifier gene MSH3 successfully blocking somatic expansion in BAC-CAG mouse models, positioning expansion modulation as a novel therapeutic avenue. Other investigational agents reflect a broadening of mechanistic targets: the C1q-targeting antibody ANX005 demonstrated manageable safety and signals of functional stabilization in patients with elevated baseline complement activity; human dental pulp stem cell therapy (NestaCell®) showed a favorable long-term safety profile with preliminary signals of motor and functional stabilization; and preclinical candidates such as GLYN122, σR/TMEM97 modulators, and mitochondrial-targeted small molecules continue to advance mechanisms including autophagy induction, reduced neuronal toxicity, and mitigation of oxidative stress. Laquinimod, despite encouraging preclinical anti-inflammatory and pro-myelination effects, failed to translate into meaningful clinical benefit.

Alongside therapeutic diversification, the field has made notable strides in biomarker and infrastructure development to support more efficient trial design. Machine learning and transcriptomic analyses have identified novel candidate targets (TXNIP, TNIP3, HTR1D, ADRB1, FOXP1), while spontaneous speech and language measures combined with plasma neurofilament light chain have emerged as promising short-term prognostic biomarkers (AUC = 0.807) for enriching and stratifying trial populations. Feasibility work through the HDClarity biofluid collection initiative has also established that research lumbar punctures are safe and acceptable within the HD community, reinforcing the infrastructure needed to support biomarker-driven trials. Collectively, these developments mark a transition from a largely symptomatic treatment paradigm toward an increasingly mechanism-diverse and biomarker-informed pipeline, even though a validated disease-modifying therapy remains elusive.